A multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of SYR-322 when used in combination with insulin in subjects with type 2 diabetes.
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Alogliptin (Primary) ; Insulin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Takeda
- 01 Dec 2009 Results were published in Diabetes, Obesity and Metabolism.
- 09 Sep 2008 Results presented at the 44th Annual Meeting of the European Association for the Study of Diabetes.
- 10 Jun 2008 Status change from in progress to completed